CA3095402A1 - Compositions and methods for treating inflammatory bowel diseases - Google Patents

Compositions and methods for treating inflammatory bowel diseases Download PDF

Info

Publication number
CA3095402A1
CA3095402A1 CA3095402A CA3095402A CA3095402A1 CA 3095402 A1 CA3095402 A1 CA 3095402A1 CA 3095402 A CA3095402 A CA 3095402A CA 3095402 A CA3095402 A CA 3095402A CA 3095402 A1 CA3095402 A1 CA 3095402A1
Authority
CA
Canada
Prior art keywords
acid
composition
subject
secondary bile
bacteria
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3095402A
Other languages
English (en)
French (fr)
Inventor
Madhumitha NANDAKUMAR
Edward J. O'brien
Sumon DATTA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seres Therapeutics Inc
Original Assignee
Seres Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seres Therapeutics Inc filed Critical Seres Therapeutics Inc
Publication of CA3095402A1 publication Critical patent/CA3095402A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3095402A 2018-03-29 2019-03-29 Compositions and methods for treating inflammatory bowel diseases Pending CA3095402A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862650002P 2018-03-29 2018-03-29
US62/650,002 2018-03-29
PCT/US2019/025010 WO2019191694A1 (en) 2018-03-29 2019-03-29 Compositions and methods for treating inflammatory bowel diseases

Publications (1)

Publication Number Publication Date
CA3095402A1 true CA3095402A1 (en) 2019-10-03

Family

ID=66429534

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3095402A Pending CA3095402A1 (en) 2018-03-29 2019-03-29 Compositions and methods for treating inflammatory bowel diseases

Country Status (10)

Country Link
US (1) US20210121505A1 (https=)
EP (1) EP3773643A1 (https=)
JP (1) JP2021519763A (https=)
KR (1) KR20200138333A (https=)
CN (1) CN112118852A (https=)
AU (1) AU2019245430A1 (https=)
BR (1) BR112020019979A2 (https=)
CA (1) CA3095402A1 (https=)
MX (1) MX2020010177A (https=)
WO (1) WO2019191694A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3668527A1 (en) 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法
TW202126317A (zh) 2019-09-24 2021-07-16 美商普拉塔生技公司 用於治療發炎和免疫疾病之組成物和方法
KR102341323B1 (ko) * 2020-07-07 2021-12-21 한국원자력의학원 미세플라스틱 노출에 의해 유도되는 뇌질환 예후 예측용 바이오마커 조성물 및 이를 이용한 예후 예측방법
CA3188645A1 (en) 2020-08-14 2022-02-17 Prolacta Bioscience, Inc. Human milk oligosaccharide compositions for use with bacteriotherapies
KR102337993B1 (ko) * 2021-10-27 2021-12-14 주식회사 바이오뱅크힐링 클로스트리디움 렙텀 균주, 및 그의 유래의 소포체 및 그의 항염증 및 항균 용도
CN115478031B (zh) * 2022-09-28 2025-04-18 中国科学院深圳先进技术研究院 防治炎症性肠病的胆汁酸代谢菌及其应用
WO2025244478A1 (ko) * 2024-05-24 2025-11-27 서울대학교병원 클로스트리디움 렙텀 균주의 염증성장질환 예방, 치료 및 진단 용도

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013035804A1 (ja) * 2011-09-08 2013-03-14 カルピス株式会社 芽胞形成菌の発芽誘起方法
JP5921894B2 (ja) * 2012-01-20 2016-05-24 アサヒカルピスウェルネス株式会社 腸内酪酸産生菌増加剤
CA2899925A1 (en) * 2013-02-04 2014-08-07 Seres Therapeutics, Inc. Compositions and methods for inhibition of pathogenic bacterial growth
MA41020A (fr) * 2014-11-25 2017-10-03 Evelo Biosciences Inc Compositions probiotiques et prébiotiques, et leurs procédés d'utilisation pour la modulation du microbiome
US20190247447A1 (en) * 2015-11-24 2019-08-15 Seres Therapeutics, Inc. Designed bacterial compositions
JP6624903B2 (ja) * 2015-11-25 2019-12-25 学校法人東京理科大学 消毒剤及び消毒方法
WO2017160711A1 (en) * 2016-03-14 2017-09-21 Holobiome, Inc. Modulation of the gut microbiome to treat mental disorders or diseases of the central nervous system
CN110545828A (zh) * 2016-04-19 2019-12-06 基因组研究有限公司 细菌疗法
JP7168558B2 (ja) * 2016-06-14 2022-11-09 ヴェダンタ バイオサイエンシーズ インコーポレーテッド Ｃｌｏｓｔｒｉｄｉｕｍ ｄｉｆｆｉｃｉｌｅ感染症の処置
EP3668527A1 (en) * 2017-08-14 2020-06-24 Seres Therapeutics, Inc. Compositions and methods for treating cholestatic disease
JP2021501185A (ja) * 2017-10-30 2021-01-14 セレス セラピューティクス インコーポレイテッド 抗生物質耐性を処置するための組成物及び方法

Also Published As

Publication number Publication date
US20210121505A1 (en) 2021-04-29
BR112020019979A2 (pt) 2021-03-09
JP2021519763A (ja) 2021-08-12
RU2020135433A (ru) 2022-04-29
KR20200138333A (ko) 2020-12-09
WO2019191694A1 (en) 2019-10-03
CN112118852A (zh) 2020-12-22
AU2019245430A1 (en) 2020-10-22
EP3773643A1 (en) 2021-02-17
MX2020010177A (es) 2021-01-15

Similar Documents

Publication Publication Date Title
US20210121505A1 (en) Compositions and methods for treating inflammatory bowel diseases
US12318412B2 (en) Faecalibacterium prausnitzii and Desulfovibrio piger for use in the treatment or prevention of diabetes and bowel diseases
JP2024099549A (ja) 設計された細菌組成物及びその使用
JP6954563B2 (ja) 代謝障害を処置するための低温殺菌アッカーマンシアの使用
JP2022548785A (ja) 炎症性疾患及び免疫疾患の治療のための組成物及び方法
AU2008310961B2 (en) Probiotics for use in relieving symptoms associated with gastrointestinal disorders
TW202034776A (zh) 長雙歧桿菌長亞種、含其的組合物及用途
Niu et al. Effect of fructooligosaccharides on the colonization of Lactobacillus rhamnosus AS 1.2466 T in the gut of mice
JP2020533008A (ja) Ｍｅｇａｍｏｎａｓ ｆｕｎｉｆｏｒｍｉｓ及びその適用
CN114745970A (zh) 促进肠道微生物群产生scfa的方法
WO2024211569A1 (en) Compositions and methods for treating or preventing clostridium difficile infection, neutropenia, cardiovascular disease, asthma, and/or cancer
JP2025508364A (ja) 健康を改善するためのシンバイオティクス処置の方法
RU2799556C2 (ru) Композиции и способы лечения воспалительных заболеваний кишечника
RU2797466C2 (ru) Faecalibacterium prausnitzii и desulfovibrio piger для применения при лечении или предупреждении диабета и заболеваний кишечника
TW202438669A (zh) 用於增強和恢復腸道上皮屏障的合生元組合物
WO2024163529A2 (en) Use of designed bacterial compositions for infection treatment
HK40129595A (zh) 用於增强和恢复肠道上皮屏障的合生元组合物
HK40109483A (zh) 液体非乳益生菌制剂治疗或预防帕金森病的用途
EA041324B1 (ru) Применение akkermansia muciniphila для лечения метаболических расстройств, увеличения расхода энергии и снижения веса, композиции, лекарственное средство

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220913